Olanzapine was licensed in the USA by the Food and Drug Administration in 2003 for the prevention of relapse in patients with bipolar disorder when the acute manic episode had responded to treatment with olanzapine. However, olanzapine is commonly used in clinical practice for preventing relapse in patients with bipolar disorder even when acute response has not been demonstrated. The aim of this systematic review and meta-analysis is to determine the effectiveness and acceptability of olanzap...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record